We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Targeted X-Ray Treatment of Mice Prevents Glaucoma

By MedImaging International staff writers
Posted on 05 Apr 2012
Researchers have demonstrated that a single, targeted X-ray treatment of a single eye in young, glaucoma-prone lab mice provided that eye with apparently life-long and typically complete protection from glaucoma.

In research published March 19, 2012, in the Journal of Clinical Investigation, Gareth Howell, PhD, Simon John, PhD, a professor at the Jackson Laboratory (Bar Harbor, ME, USA), and colleagues also used advanced genomics applications to discover some of the very first pathways to change during glaucoma in these mice. The first pathway they identified to change suggests a critical process that could be responsible for the earliest damage that glaucoma inflicts on the optic nerve.

Glaucoma, a leading cause of blindness, affects more than four million people in the United States alone, at least half of whom do not even know they have the disease. Current treatments target intraocular pressure elevation, the best-known risk factor for glaucoma. However, blindness-inducing damage to retinal ganglion cells and the optic nerve can occur in patients with normal intraocular eye pressure. Earlier detection and better treatments could therefore have a powerful impact on preventing blindness due to glaucoma.

Approximately a decade ago, the John lab made the remarkable discovery that just a single dose of whole-body irradiation along with bone marrow transfer conferred an unprecedented protection against glaucoma. Ninety-six percent of treated eyes had no glaucoma a year later compared to only 20% of control eyes.

Although this result was unexpected, there is some evidence that radiation may protect from human glaucoma. Epidemiologists who tracked Japanese survivors of the atomic bombings in World War II had noticed that exposure to radiation increased the incidence of thyroid and other cancers but seemed to provide protection against glaucoma.

The John labs’ new demonstration that irradiation of just one eye is protective, and at lower doses than they previously published, raises the possibility of using very controlled localized radiation of just the eye to prevent human glaucoma.

Further research in other animal models to assess protection as well as safety and effectiveness is necessary before attempting human treatments. However, as the authors concluded in their article, “Given both the robust and long-term efficacy of a single dose of X-ray radiation in preventing cellular entry into the optic nerve and retina, it will be important to further evaluate the use of X-rays for preventing glaucoma.”

The study demonstrated that in response to early tissue stresses, a type of immune cells called monocytes, enter the optic nerve and retina in glaucoma. These monocytes express damaging molecules that appear critical for nerve damage in glaucoma. The entry of these cells is controlled in part by endothelial cells that line blood vessels. Radiation treatment appears to change how these endothelial cells respond to the early tissue stresses and affect the entry of the monocytes into the optic nerve and retina.

“While more work is needed to fully understand how the radiation confers long-term protection,” Dr. Howell said, “radiation appears to hinder the adhesion and migration of monocytes into the areas of the eye prone to nerve damage.” This finding strongly implicates the entry of cells into the eye as a key component of the nerve damage that leads to blindness. It also suggests vision may be maintained in eyes with high intraocular pressure by treatments that block the entry of monocytes into the eye.

The Jackson Laboratory is an independent, nonprofit biomedical research institution and US National Cancer Institute (Bethesda, MD, USA)-designated cancer center based in Bar Harbor, Maine, with a facility in Sacramento, CA, USA, an institute for genomic medicine planned in Farmington, CT, USA, and a total staff of approximately 1,400. Its goal is to uncover the genetic basis for preventing, treating, and curing human disease, and to enable research and education for the global biomedical community.

Related Links:

Jackson Laboratory


Computed Tomography System
Aquilion ONE / INSIGHT Edition
X-Ray Illuminator
X-Ray Viewbox Illuminators
Ultrasound Imaging System
P12 Elite
Portable X-ray Unit
AJEX140H

Channels

Ultrasound

view channel
Image: The new implantable device for chronic pain management is small and flexible (Photo courtesy of The Zhou Lab at USC)

Wireless Chronic Pain Management Device to Reduce Need for Painkillers and Surgery

Chronic pain affects millions of people globally, often leading to long-term disability and dependence on opioid medications, which carry significant risks of side effects and addiction.... Read more

Nuclear Medicine

view channel
Image: The diagnostic tool could improve diagnosis and treatment decisions for patients with chronic lung infections (Photo courtesy of SNMMI)

Novel Bacteria-Specific PET Imaging Approach Detects Hard-To-Diagnose Lung Infections

Mycobacteroides abscessus is a rapidly growing mycobacteria that primarily affects immunocompromised patients and those with underlying lung diseases, such as cystic fibrosis or chronic obstructive pulmonary... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.